Paperless validation will help fuel fast paced advancements in life science research, translational and consumer genomics, and molecular diagnostics.
SAN FRANCISCO, Oct. 8, 2018 /PRNewswire/
ValGenesis, Inc., the market leader in Enterprise Validation Lifecycle Management Solutions (VLMS) today announced that a global leader in genomics has chosen ValGenesis’ 100% paperless Validation Lifecycle Management System to manage its corporate validation lifecycle process.
This global leader in genomics develops, manufactures, and markets leading-edge life science tools and systems for large-scale analysis of genetic variations and functions in fields ranging from cancer research to agriculture. Their systems are enabling studies that were not even imaginable just a few short years ago, moving the world closer to the realization of personalized medicine. With over 7000 employees across the globe, the company has developed a comprehensive line of products to advance disease research, drug development, and the development of molecular tests. Its broad range of customers include academia, government, pharmaceuticals, biotechnology, and other leading institutions across the globe.
Recognizing that traditional, manual, paper-based validation processes are costly and inefficient, the company selected ValGenesis Enterprise VLMS—an electronic, paperless, cloud-based SaaS solution that well meets its lifecycle validation needs. ValGenesis VLMS comes with multi-site and multilingual capabilities to standardize the validation process across a global organization. With this system, the company will significantly reduce validation cycle time, gain a higher standard of data integrity, improve its regulatory compliance process, and gain a holistic view of real-time validation status across the organization, thereby improving the quality and speed of the entire validation process.
“ValGenesis has proven its value to all types of life science companies and is delighted to add another new client in the genomic space, which is focused on solutions ranging from cancer research to agriculture,” said Narayan Raj, Vice President of ValGenesis Inc. “ValGenesis continues its commitment to leading the industry in offering purpose-driven solutions such as the ValGenesis VLMS, which is setting the standard for how paperless validation lifecycle systems improve quality assurance and regulatory compliance for life science organizations around the world.”
Althea D’Sylva, ValGenesis Communications, +1 510 648 3646 Ex. 1018,
ValGenesis, Inc. is the inventor of an innovative software platform serving as the foundation for managing compliance-based validation activities in Life Sciences companies. ValGenesis, Inc. provides the first enterprise application that manages the corporate validation lifecycle process. As the only system for managing validation execution and approval 100% electronically, ValGenesis was selected by an industry peer review committee to receive the Parenteral Drug Association (PDA) New Innovative Technology Award.
The solution is fully compliant with U.S. FDA 21 CFR Part 11 and Annex 11 requirements. For more information, visit https://www.valgenesis.com